Physician profile
Katrina Gateley
NPI 1265203194
$6,129.32
in general payments reported to CMS, 2019-2025
26 companies · $3,296 in 2025
The $3,296 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,834 · 2025: $3,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,129.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.30 | 2024-2025 | |
| Viiv Healthcare Company | $726.15 | 2024-2025 | Dovato, Cabenuva, Apretude |
| Astrazeneca Pharmaceuticals LP | $620.09 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $551.65 | 2024-2025 | Arexvy, Shingrix, Nucala |
| Pfizer INC. | $342.46 | 2024-2025 | |
| Ardelyx, INC. | $332.83 | 2024-2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $290.02 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $243.80 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $221.57 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $219.16 | 2024-2025 | Auvelity, Symbravo |
| Lundbeck LLC | $178.57 | 2024-2025 | Rexulti |
| Abbott Laboratories | $145.28 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $144.19 | 2024-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $140.99 | 2024-2025 | |
| Lilly USA, LLC | $116.05 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.40 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $87.06 | 2024-2025 | Pifeltro, Delstrigo, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $56.87 | 2024 | Austedo Xr |
| Indivior INC. | $40.32 | 2024-2025 | Sublocade |
| Alkermes, INC. | $39.81 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Ironwood Pharmaceuticals, INC | $37.79 | 2024 | |
| Neurocrine Biosciences, INC. | $35.43 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $33.86 | 2025 | Zoryve |
| Amgen INC. | $30.13 | 2025 | Repatha, Otezla |
| Phadia US INC. | $16.75 | 2025 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $15.79 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Gateley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.